Ying Yuan, Ph.D.

Peer-Reviewed Articles

1. Cress GA, Scudiero KT, Wang F, Patrick VB, Wood PM, Yuan Y, Lowe ME, Uc A. Patient and Family Input to Determine Experiences and Research Interests in Pediatric Pancreatitis: An INSPPIRE-2 Study. Pancreas 54(1):e18-e22, 2025. PMID: 39259842.
2. Zhang H, Wu J, Miao Y, Yuan Y, Qu Z, Zhang Y, Hua Z. Determination of the Optimal Volume of 0.5% Ropivacaine in Single-injection Retroclavicular Brachial Plexus Block for Arthroscopic Shoulder Surgery: A Phase I/II Trial. Anesthesiology 142(1):155-165, 2025. PMID: 39018520.
3. Sellers ZM, Giefer MJ, Wang F, Cress GA, Abu-El-Haija MA, Chugh A, Cohen RZ, Downs EM, Fishman DS, Freeman AJ, Gariepy CE, Gonska TY, Grover AS, Lindblad D, Liu QY, Maqbool A, Mark JA, McFerron BA, Mehta MS, Morinville VD, Ng K, Noel RA, Ooi CY, Perito ER, Phadke MY, Ruan W, Schwarzenberg SJ, Troendle DM, Wilschanski M, Zheng Y, Yuan Y, Lowe ME, Uc A. Impact of Elevated Serum Triglycerides on Children with Acute Recurrent or Chronic Pancreatitis from INSPPIRE-2. J Pediatr 276(None):114298, 2025. PMID: 39277078.
4. Piha-Paul, SA, Tseng, C, Leung, CH, Yuan, Y, Karp, DD, Subbiah, V, Hong, DS, Fu, S, Naing, A, Rodon Ahnert, J, Javle, M, Ajani, JA, Raghav, KS, Somaiah, N, Mills, GB, Tsimberidou, AM, Zheng, X, Chen, K, Meric-Bernstam, F. Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations. npj Precision Oncology 8(1), 2024. PMID: 39085400.
5. Rauh-Hain JA, Melamed A, Pareja R, May T, Sinno A, McNally L, Horowitz NS, De Iaco P, Michener CM, Van Lonkhuijzen L, Iniesta MD, Yuan Y, Ramirez PT, Fagotti A. Laparoscopic Cytoreduction After Neoadjuvant Chemotherapy in High-Grade Epithelial Ovarian Cancer: A LANCE Randomized Clinical Trial. JAMA Netw Open 7(11):e2446325, 2024. PMID: 39570589.
6. Lin, TA, McCaw, ZR, Koong, A, Lin, C, Abi Jaoude, J, Patel, RR, Kouzy, R, El Alam, MB, Sherry, AD, Noticewala, SS, Fuller, CD, Thomas, CR, Sun, R, Lee, JJ, Lin, R, Yuan, Y, Shyr, Y, Meirson, T, Ludmir, EB. Proportional Hazards Violations in Phase III Cancer Clinical Trials. Clinical cancer research : an official journal of the American Association for Cancer Research 30(20):4791-4799, 2024. PMID: 39133081.
7. Wang S, Thall PF, Takeda K, Yuan Y. ROMI: a randomized two-stage basket trial design to optimize doses for multiple indications. Biometrics 80(4):None, 2024. PMID: 39360905.
8. Pan J, Tan Y, Shan L, Seery S, Deng B, Ling Z, Xu J, Duan J, Wang Z, Wang K, Yu X, Zheng Q, Xu X, Hu G, Tan T, Yuan Y, Tian Z, Yan F, Han Y, Zhang J, Feng X. Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trial. Nat Med None(None):None, 2024. PMID: 39354195.
9. Freeman AJ, Ng K, Wang F, Abu-El-Haija MA, Chugh A, Cress GA, Fishman DS, Gariepy CE, Giefer MJ, Goday P, Gonska TY, Grover AS, Lindblad D, Liu QY, Maqbool A, Mark JA, McFerron BA, Mehta MS, Morinville VD, Noel RA, Ooi CY, Perito ER, Schwarzenberg SJ, Sellers ZM, Wilschanski M, Zheng Y, Yuan Y, Andersen DK, Lowe ME, Uc A. Pancreatic Enzyme Use Reduces Pancreatitis Frequency in Children With Acute Recurrent or Chronic Pancreatitis: A Report From INSPPIRE. Am J Gastroenterol 119(10):2094-2102, 2024. PMID: 38517077.
10. Chaftari, AP, Dagher, H, Hachem, RY, Jiang, Y, Lamie, PM, Dib, RW, John, TM, Haddad, AJ, Philip, A, Alii, S, Mulanovich, P, Yuan, Y, Chaftari, P, Raad, II. A randomized non-inferiority study comparing imipenem/cilastatin/relebactam with standard-of-care Gram-negative coverage in cancer patients with febrile neutropenia. Journal of Antimicrobial Chemotherapy 79(10):2543-2553, 2024. PMID: 39092963.
11. Lu M, Yuan Y, Liu S. A Bayesian pharmacokinetics integrated phase I-II design to optimize dose-schedule regimes. Biostatistics None(None):None, 2024. PMID: 39275895.
12. Zhao L, Li C, Zuo S, Han Y, Deng B, Ling Z, Zhang Y, Peng S, Xu J, Duan J, Wang Z, Yu X, Zheng Q, Xu X, Yuan Y, Tian Z, Tang K, Zhang Y, Niu Q, Zhang J, Chang AH, Luo Y, Feng X, Pan J. Autologous CD7 CAR-T cells generated without T cell pre-selection in pediatric patients with relapsed/refractory T-ALL: A phase I trial. Mol Ther None(None):None, 2024. PMID: 39244642.
13. Yang, P, Hubert, SM, Futreal, PA, Song, X, Zhang, J, Lee, JJ, Wistuba, II, Yuan, Y, Zhang, J, Li, Z. A NOVEL BAYESIAN MODEL FOR ASSESSING INTRATUMOR HETEROGENEITY OF TUMOR INFILTRATING LEUKOCYTES WITH MULTIREGION GENE EXPRESSION SEQUENCING. Annals of Applied Statistics 18(3):1879-1898, 2024. PMID: None.
14. How JA, Dang M, Lee S, Fellman B, Westin SN, Sood AK, Fleming ND, Shafer A, Yuan Y, Liu J, Zhao L, Celestino J, Hajek R, Morgan MB, Parra ER, Laberiano Fernandez CD, Arrechedera CA, Solis Soto LM, Schmeler KM, Nick A, Lu KH, Coleman R, Wang L, Jazaeri AA. Pembrolizumab plus chemotherapy in frontline treatment of advanced ovarian cancer: Clinical and translational results from a phase 2 trial. Med None(None):100494, 2024. PMID: 39151421.
15. Tang, C, Hartley, G, Couillault, CA, Yuan, Y, Lin, Y, Nicholas, C, Srinivasamani, A, Dai, J, Ileana Dumbrava, EE, Fu, S, Karp, DD, Naing, A, Piha-Paul, SA, Rodon Ahnert, J, Pant, S, Subbiah, V, Yap, T, Tsimberidou, AM, Guerrero, PA, Dhebat, S, Proia, T, Curran, M, Hong, DS. Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer. BMJ Oncology 3(1), 2024. PMID: None.
16. Son, J, Zhang, Y, Lin, Y, Mirallas, O, Ballesteros, PA, Nardo, M, Clark, N, Hillman, RT, Campbell, E, Holla, V, Johnson, A, Biter, A, Yuan, Y, Cobb, LP, Gershenson, DM, Jazaeri, AA, Lu, KH, Soliman, PT, Westin, SN, Euscher, ED, Lawson, BC, Yang, RK, Meric-Bernstam, F, Hong, DS. Clinical and Genomic Landscape of RAS Mutations in Gynecologic Cancers. Clinical Cancer Research 30(14):2986-2995, 2024. PMID: 38687597.
17. Yang, P, Li, D, Lin, R, Huang, B, Yuan, Y. Design and sample size determination for multiple-dose randomized phase II trials for dose optimization. Statistics in Medicine 43(15):2972-2986, 2024. PMID: 38747472.
18. Mu R, Zhan X, Tang RS, Yuan Y. A Bayesian latent-subgroup platform design for dose optimization. Biometrics 80(3):None, 2024. PMID: 39253988.
19. Gouda, MA, Shunyakova, J, Naing, A, Ileana Dumbrava, EE, Hong, DS, Yuan, Y, Yang, P, Myers, AL, Liang, Y, Peng, J, Karp, DD, Tsimberidou, AM, Rodon Ahnert, J, Yap, TA, Piha-Paul, SA, Meric-Bernstam, F, Fu, S. A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors. ESMO Open 9(6), 2024. PMID: 38914452.
20. Yuan Y, Zhou H, Liu S. Statistical and practical considerations in planning and conduct of dose-optimization trials. Clin Trials 21(3):17407745231207085, 2024. e-Pub 2024. PMID: 38243399.
21. Tian, F, Lin, R, Wang, L, Yuan, Y. A Bayesian quasi-likelihood design for identifying the minimum effective dose and maximum utility dose in dose-ranging studies. Statistical Methods in Medical Research 33(6):931-944, 2024. PMID: 38573788.
22. Knisely, A, Hinchcliff, EM, Gardiner, E, Rangwala, R, Lito, K, Fellman, B, Yuan, Y, Sood, AK, Westin, SN, Lu, KH, Jazaeri, AA. Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer. iScience 27(5), 2024. PMID: 38726365.
23. Hinchcliff EM, Knisely A, Adjei N, Fellman B, Yuan Y, Patel A, Xu C, Westin SN, Sood AK, Soliman PT, Shafer A, Fleming ND, Gershenson DM, Vikram R, Bathala T, Vining D, Ganeshan DM, Lu KH, Sun CC, Meyer LA, Jazaeri AA. Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer. Cancer 130(7):1061-1071, 2024. e-Pub 2023. PMID: 38009662.
24. Guo, B, Laird, G, Song, Y, Chen, J, Yuan, Y. Adaptive hybrid control design for comparative clinical trials with historical control data. Journal of the Royal Statistical Society. Series C: Applied Statistics 73(2):444-459, 2024. PMID: None.
25. Chi, X, Yuan, Y, Yu, Z, Lin, R. A generalized calibrated Bayesian hierarchical modeling approach to basket trials with multiple endpoints. Biometrical Journal 66(2), 2024. PMID: 38368277.
26. Zang Y, Thall PF, Yuan Y. A generalized phase 1-2-3 design integrating dose optimization with confirmatory treatment comparison. Biometrics 80(1), 2024. PMID: 38364811.
27. Hui C, Brown E, Wong S, Das M, Wakelee H, Neal J, Ramchandran K, Myall NJ, Pham D, Xing L, Yang Y, Kovalchuk N, Yuan Y, Lu Y, Xiang M, Chin A, Diehn M, Loo BW Jr, Vitzthum LK. Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer: Protocol for a Bayesian Optimal Phase I/II Trial. Clin Lung Cancer 25(2):186-189, 2024. PMID: 38040540.
28. Lilly MB, Wu C, Ke Y, Chen WP, Soloff AC, Armeson K, Yokoyama NN, Li X, Song L, Yuan Y, McLaren CE, Zi X. A phase I study of docetaxel plus synthetic lycopene in metastatic prostate cancer patients. Clin Transl Med 14(3):e1627, 2024. PMID: 38515274.
29. Dasgupta P, Ou A, Lin H, Gregory T, Alfaro-Munoz KD, Yuan Y, Afshar-Khargan V, Kamiya-Matsuoka C, Rousseau JF, Majd NK. The risk and burden of thromboembolic and hemorrhagic events in patients with malignant gliomas receiving bevacizumab. J Neurooncol. e-Pub 2024. PMID: 38372903.
30. Zhao Y, Yuan Y, Korn EL, Freidlin B. Backfilling Patients in Phase I Dose Escalation Trials Using Bayesian Optimal Interval Design (BOIN). Clin Cancer Res 30(4):673-679, 2024. PMID: 38048044.
31. Amaria R, Knisely A, Vining D, Kopetz S, Overman MJ, Javle M, Antonoff MB, Tzeng CD, Wolff RA, Pant S, Lito K, Rangel K, Fellman B, Yuan Y, Lu KH, Sakellariou-Thompson D, Haymaker CL, Forget MA, Hwu P, Bernatchez C, Jazaeri AA. Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. J Immunother Cancer 12(2), 2024. e-Pub 2024. PMID: 38309721.
32. Nowlen CJ, Daniels M, Uzunparmak B, Ileana Dumbrava EE, Yuan Y, Patel KP, Rayes N, Harkenrider J, Wathoo C, Veazie J, Luna KA, Wang W, Horombe C, Javle M, Ahnert JR, Yap TA, Arun B, Lu KH, Meric-Bernstam F. Limited Independent Follow-Up with Germline Testing of Variants Detected in BRCA1 and BRCA2 by Tumor-Only Sequencing. J Immunother Precis Oncol 7(1):7-17, 2024. PMID: 38327755.
33. Zhang W, Laird G, Chen J, Yuan Y. A Bayesian phase II proof-of-concept design for clinical trials with longitudinal endpoints. Stat Med 43(1):173-183, 2024. e-Pub 2023. PMID: 37937591.
34. Chen, K, Wang, L, Yuan, Y. MT-Keyboard: A Bayesian Model-Assisted Interval Design to Account for Toxicity Grades and Types for Phase I Trials. Statistics in Biopharmaceutical Research 16(3):305-314, 2024. PMID: None.
35. Yang, JY, Li, GC, Yuan, Y. Accelerate vaccine development using seamless phase 2/3 trial designs. Expert Review of Vaccines 23(1):523-534, 2024. PMID: 38682812.
36. Liu, R, Yuan, Y, Sen, S, Marchenko, O, Jiang, Q, Tian, H, Li, X, Lin, R, Lu, C, Zhou, H. Design Strategy and Consideration for Oncology Dose-Optimization. Statistics in Biopharmaceutical Research 16(3):338-347, 2024. PMID: None.
37. Fogel, EL, Easler, JJ, Yuan, Y, Yadav, D, Conwell, DL, Vege, SS, Han, S, Park, WG, Patrick, V, White, FA. Safety, Tolerability, and Dose-Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis. JMIR Research Protocols 13(1), 2024. PMID: 38451604.
38. Dejardin D, Huang B, Yuan Y, Beyer U, Fridlyand J, Zhu J. Dose Optimization for Novel Oncology Agents: Design Options and Strategies. Stat Biopharm Res 16(3):326–337, 2024. PMID: None.
39. Guo B, Wang L, Yuan Y. Treatment Comparisons in Adaptive Platform Trials Adjusting for Temporal Drift. Statistics in Biopharmaceutical Research 16(3):361–370, 2024. PMID: None.
40. Msaouel P, Yu K, Yuan Y, Chen J, Yan X, Karki M, Duan F, Sheth R, Rao P, Sircar K, Shah A, Zurita A, Genovese G, Li M, Yeh C, Dang M, Han G, Chu Y, Hallin M, Olson P, Yang R, Slavin D, Der-Torossian H, Chin C, Tannir N, Wang L, Gao J. Sitravatinib in combination with nivolumab plus ipilimumab in patients with advanced clear cell renal cell carcinoma: a phase 1 trial. Nature Communications None(None):None, 2024. PMID: None.
41. Jiang L, Yin Z, Yan F, Yuan Y. MC-Keyboard: A practical phase I trial design for tar geted therapies and immunotherapies integrating multiple-grade toxicities. Journal of Immunotherapy and Precision Oncology 7(3):159–167, 2024. PMID: None.
42. Ye J, Pan H, Reaman G, Roychoudhury S, Lu C, Renfro LA, Ji Y, Liu R, Yuan Y, Zhang W. Considerations for External Control in Pediatric Oncology. Medical Research Archieves 12(1):None, 2024. PMID: None.
43. D'Angelo G, Gong M, Marshall J, Yuan Y, Li X. U-MET: Utility-Based Dose Optimization Approach for Multiple-Dose Randomized Trial Designs. Stat Biopharm Res None(None):None, 2024. PMID: None.
44. Lu M, Zhang J, Yuan Y, Lin R. Comb-BOIN12: A Utility-Based Bayesian Optimal Interval Design for Dose Optimization in Cancer Drug-Combination Trials. Stat Biopharm Res None(None):None, 2024. PMID: None.
45. Subbiah V, Coleman N, Piha-Paul SA, Tsimberidou AM, Janku F, Rodon J, Pant S, Dumbrava EE, Fu S, Hong DS, Zhang S, Sun M, Jiang Y, Roszik J, Song J, Yuan Y, Meric-Bernstam F, Naing A. Phase I study of mTORC1/2 inhibitor sapanisertib in combination with metformin in patients with mTOR/AKT/PI3K pathway alterations and advanced solid malignancies. Cancer Res Commun. e-Pub 2023. PMID: 38126764.
46. Yang P, Zhao Y, Nie L, Vallejo J, Yuan Y. SAM: Self-adapting mixture prior to dynamically borrow information from historical data in clinical trials. Biometrics 79(4):2857-2868, 2023. e-Pub 2023. PMID: 37721513.
47. Guo B, Yuan Y. DROID: dose-ranging approach to optimizing dose in oncology drug development. Biometrics 79(4):2907-2919, 2023. PMID: 36807110.
48. Taniguchi CM, Frakes JM, Aguilera TA, Palta M, Czito B, Bhutani MS, Colbert LE, Abi Jaoude J, Bernard V, Pant S, Tzeng CD, Kim DW, Malafa M, Costello J, Mathew G, Rebueno N, Koay EJ, Das P, Ludmir EB, Katz MHG, Wolff RA, Beddar S, Sawakuchi GO, Moningi S, Slack Tidwell RS, Yuan Y, Thall PF, Beardsley RA, Holmlund J, Herman JM, Hoffe SE. Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, phase 1b/2 trial. Lancet Oncol 24(12):1387-1398, 2023. PMID: 38039992.
49. Abu-El-Haija, M, Hornung, L, Ellery, KM, Fishman, D, Gonska, T, Gariepy, CE, Lowe, ME, Larson Ode, K, Maqbool, A, Mascarenhas, MR, Morinville, VD, Ooi, CY, Perito, ER, Schwarzenberg, SJ, Sellers, ZM, Zemel, BS, Yuan, Y, Wang, F, Uc, A, Kalkwarf, HJ. Bone health in children with recurrent and chronic pancreatitis. Pancreatology 23(7):755-760, 2023. PMID: 37723006.
50. Uzunparmak B, Haymaker C, Raso G, Masciari S, Wang L, Lin H, Gorur A, Kirby B, Cimo AM, Kennon A, Ding Q, Urschel G, Yuan Y, Feng G, Rizvi Y, Hussain A, Zhu C, Kim P, Abbadessa G, Subbiah V, Yap TA, Rodon J, Piha-Paul SA, Meric-Bernstam F, Dumbrava EE. HER2-low expression in patients with advanced or metastatic solid tumors. Ann Oncol 34(11):1035-1046, 2023. PMID: 37619847.
51. Yang P, Hubert SM, Futreal PA, Song X, Zhang J, Lee JJ, Wistuba I, Yuan Y, Zhang J, Li Z. A novel Bayesian model for assessing intratumor heterogeneity of tumor infiltrating leukocytes with multi-region gene expression sequencing. bioRxiv, 2023. e-Pub 2023. PMID: 37961165.
52. Jiang L, Thall PF, Yan F, Kopetz S, Yuan Y. BASIC: A Bayesian adaptive synthetic-control design for phase II clinical trials. Clin Trials 20(5):17407745231176445, 2023. PMID: 37313712.
53. Morinville VD, Husain SZ, Wang F, Cress GA, Abu-El-Haija M, Chugh A, Downs E, Ellery K, Fishman DS, Freeman AJ, Gariepy CE, Giefer M, Gonska T, Liu Q, Maqbool A, Mark J, Mcferron BA, Mehta M, Nathan JD, Ng K, Ooi CY, Perito E, Ruan W, Schwarzenberg SJ, Sellers ZM, Serrano J, Troendle DM, Wilschanski M, Zheng Y, Yuan Y, Lowe M, Uc A, Chronic Pancreatitis CFTSO, Diabetes, Cancer P. Pediatric Drug-Associated Pancreatitis Reveals Concomitant Risk Factors and Poor Reliability of Causality Scoring. J Pediatr Gastroenterol Nutr 77(4):540-546, 2023. PMID: 37496124.
54. Cao H, Yao C, Yuan Y. Bayesian approach for design and analysis of medical device trials in the era of modern clinical studies. Med Rev (2021) 3(5):408-424, 2023. PMID: 38283256.
55. Jiang L, Yuan Y. Seamless Phase II/III Design: A Useful Strategy to Reduce the Sample Size for Dose Optimization. J Natl Cancer Inst 115(9):1092-1098, 2023. PMID: 37243720.
56. Stephen B, Hajjar J, Sarda S, Duose DY, Conroy JM, Morrison C, Alshawa A, Xu M, Zarifa A, Patel SP, Yuan Y, Kwiatkowski E, Wang L, Rodon Ahnert J, Fu S, Meric-Bernstam F, Lowman GM, Looney T, Naing A. T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy. J Immunother Cancer 11(8), 2023. PMID: 37604642.
57. Zhao Y, Li D, Liu R, Yuan Y. Bayesian optimal phase II designs with dual-criterion decision making. Pharm Stat 22(4):605-618, 2023. PMID: 36871961.
58. Thall, PF, Zang, Y, Yuan, Y. Generalized phase I-II designs to increase long term therapeutic success rate. Pharmaceutical statistics 22(4):692-706, 2023. PMID: 37038957.
59. Zhao, Y, Tang, R, Du, Y, Yuan, Y. A Bayesian platform trial design to simultaneously evaluate multiple drugs in multiple indications with mixed endpoints. Biometrics 79(2):1459-1471, 2023. PMID: 35546501.
60. Zhou Y, Zhao Y, Cicconetti G, Mu Y, Yuan Y, Wang L, Penugonda S, Salman Z. AIDE: Adaptive intrapatient dose escalation designs to accelerate Phase I clinical trials. Pharm Stat 22(2):300-311, 2023. PMID: 36333972.
61. Raghav K, Kopetz S, Yuan Y. Reply to Y. Yu et al. J Clin Oncol 41(7):JCO2202588, 2023. PMID: 36595731.
62. Jiang L, Nie L, Yuan Y. Elastic priors to dynamically borrow information from historical data in clinical trials. Biometrics 79(1):49-60, 2023. PMID: 34437714.
63. Son J, Lin HY, Fu S, Biter AB, Dumbrava EE, Karp DD, Naing A, Pant S, Piha-Paul SA, Rodon J, Subbiah V, Tsimberidou AM, Yap TA, Frumovitz MM, Jazaeri AA, Ramirez PT, Westin SN, Yuan Y, Meric-Bernstam F, Hong DS. Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer. J Immunother Precis Oncol 6(1):10-18, 2023. PMID: 36751659.
64. Gregory TA, Mastall M, Lin H, Hess KR, Yuan Y, Martin-Bejarano Garcia M, Fuller GN, Alfaro KD, Gule-Monroe MK, Huse JT, Khatua S, Rao G, Sandberg DI, Wefel JS, Yeboa DN, Paulino AC, McGovern SL, Zaky W, Mahajan A, Suki D, Weathers SP, Harrison RA, de Groot JF, Puduvalli VK, Penas-Prado M, Majd NK. Characterization of recurrence patterns and outcomes of medulloblastoma in adults: The University of Texas MD Anderson Cancer Center experience. Neurooncol Adv 5(1):vdad032, 2023. PMID: 37114244.
65. Qing, Y, Thall, PF, Yuan, Y. A Bayesian piecewise exponential phase II design for monitoring a time-to-event endpoint. Pharmaceutical statistics 22(1):34-44, 2023. PMID: 35851545.
66. Thall PF, Zang Y, Chapple AG, Yuan Y, Lin R, Marin D, Msaouel P. Novel clinical trial designs with dose optimization to improve long-term outcomes. Clin Cancer Res 29(22):4549-4554, 2023. PMID: 37725573.
67. Huang B, Yuan Y. Design Strategies for Dose Optimization in Oncology Drug Development. Biopharmaceutical Report 30(2):27-31, 2023. PMID: None.
68. Chandra N, Muller P, Yuan Y, De GJ. Bayesian Nonparametric Common Atoms Re gression for Generating Synthetic Controls in Clinical Trials. The Journal of the American Statistical Association 118(None):2301–2314, 2023. PMID: None.
69. Marchenko O, Sridhara R, Jiang Q, Barksdale E, Ando Y, Alwis DD, Brown K, Fernandes L, Van Bussel MTJ, Choo Q, Coory M, Garrett-Mayer E, Gwise T, Hess L, Liu R, Mandrekar S, Ouellet D, Pinheiro J, Posch M, Rahman NA, Rantell KR, Raven A, Sarem S, Sen S, Shah M, Shen YL, Simon R, Theoret M, Yuan Y, Pazdur R. Designing Dose-Optimization Studies in Cancer Drug Development: Discussions with Regulators. Statistics in Biopharmaceutical Research 15(None):697-703, 2023. PMID: None.
70. Lin, R, Shi, H, Yin, G, Thall, PF, Yuan, Y, Flowers, CR. BAYESIAN HIERARCHICAL RANDOM-EFFECTS META-ANALYSIS AND DESIGN OF PHASE I CLINICAL TRIALS. Annals of Applied Statistics 16(4):2481-2504, 2022. PMID: 36329718.
71. Yuan Y, Zhao Y. Commentary on "Improving the performance of Bayesian logistic regression model with overdose control in oncology dose-finding studies". Stat Med 41(27):5484-5490, 2022. PMID: 36394102.
72. Uc A, Cress GA, Wang F, Abu-El-Haija M, Ellery KM, Fishman DS, Gariepy CE, Gonska T, Lin TK, Liu QY, Mehta M, Maqbool A, McFerron BA, Morinville VD, Ooi CY, Perito ER, Schwarzenberg SJ, Sellers ZM, Serrano J, Shah U, Troendle DM, Wilschanski M, Zheng Y, Yuan Y, Lowe ME, Chronic Pancreatitis CFTSO, Diabetes, Cancer P. Analysis of INSPPIRE-2 Cohort: Risk Factors and Disease Burden in Children With Acute Recurrent or Chronic Pancreatitis. J Pediatr Gastroenterol Nutr 75(5):643-649, 2022. e-Pub 2022. PMID: 35976273.
73. Yap, TA, Ngoi, NY, Dumbrava, EE, Karp, DD, Rodon Ahnert, J, Fu, S, Hong, DS, Naing, A, Pant, S, Piha-Paul, SA, Subbiah, V, Tsimberidou, AM, Dufner, D, Rhudy, J, Gore, SD, Ivy, SP, Yuan, Y, Westin, SN, Mills, GB, Meric-Bernstam, F. NCI10329. European Journal of Cancer 174:S7, 2022. PMID: None.
74. Ngoi, NY, Pilie, PG, Piha-Paul, SA, Dumbrava, EE, Fu, S, Hong, DS, Karp, DD, Naing, A, Pant, S, Rodon Ahnert, J, Subbiah, V, Tsimberidou, AM, Salguero, C, Brown, CV, Hoadley, WE, Johnson, A, Yuan, Y, Westin, SN, Meric-Bernstam, F, Yap, TA. DNA Damage Response (DDR) Basket of Baskets (D-BOB) Trial. European Journal of Cancer 174:S10, 2022. PMID: None.
75. Ng, SP, Cardenas, CE, Bahig, H, Elgohari, B, Wang, J, Johnson, JM, Moreno, AC, Shah, SJ, Garden, AS, Phan, J, Gunn, GB, Frank, SJ, Ding, Y, Na, L, Yuan, Y, Urbauer, D, Mohamed, AS, Rosenthal, D, Morrison, WH, MacManus, M, Fuller, C. Changes in Apparent Diffusion Coefficient (ADC) in Serial Weekly MRI during Radiotherapy in Patients with Head and Neck Cancer. Current Oncology 29(9):6303-6313, 2022. PMID: 36135064.
76. How JA, Jazaeri AA, Fu S, Rodon Ahnert J, Gong J, Stephen B, Ferreira Dalla Pria H, Bhosale P, Johnson A, Yuan Y, Meric-Bernstam F, Naing A. Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials. Cancers (Basel) 14(15):3695(15), 2022. PMID: 35954359.
77. Lu, M, Liu, S, Yuan, Y. Why there are so many contradicted or exaggerated findings in highly-cited clinical research?. Contemporary Clinical Trials 118, 2022. PMID: 35525531.
78. Chaftari, AP, Hachem, RY, Malek, A, Mulanovich, VE, Szvalb, AD, Jiang, Y, Yuan, Y, Ali, S, Deeba, R, Chaftari, P, Raad, II. A Prospective Randomized Study Comparing Ceftolozane/Tazobactam to Standard of Care in the Management of Neutropenia and Fever in Patients With Hematological Malignancies. Open Forum Infectious Diseases 9(6), 2022. PMID: 35663286.
79. Zhou Y, Lin R, Lee JJ, Li D, Wang L, Li R, Yuan Y. TITE-BOIN12: A Bayesian phase I/II trial design to find the optimal biological dose with late-onset toxicity and efficacy. Stat Med 41(11):1918-1931, 2022. PMID: 35098585.
80. Tham SW, Wang F, Gariepy CE, Cress GA, Abu-El-Haija MA, Bellin MD, Ellery KM, Fishman DS, Gonska T, Heyman MB, Lin TK, Maqbool A, McFerron BA, Morinville VD, Nathan JD, Ooi CY, Perito ER, Schwarzenberg SJ, Sellers ZM, Shah U, Troendle DM, Wilschanski M, Zheng Y, Yuan Y, Lowe ME, Uc A, Palermo TM, a cuRE ISGOPPISF, Chronic Pancreatitis CFTSO, Diabetes, Cancer P. Health-Related Quality of Life in Pediatric Acute Recurrent or Chronic Pancreatitis: Association with Biopsychosocial Risk Factors. J Pediatr Gastroenterol Nutr 74(5):636-642, 2022. PMID: 35192575.
81. Msaouel, P, Goswami, S, Thall, PF, Wang, X, Yuan, Y, Jonasch, E, Gao, J, Campbell, M, Shah, AY, Corn, P, Tam, AL, Ahrar, K, Rao, P, Sircar, K, Cohen, L, Basu, S, Duan, F, Jindal, S, Zhang, Y, Chen, H, Yadav, SS, Shazer, R, Der-Torossian, H, Allison, JP, Sharma, P, Tannir, NM. A phase 1-2 trial of sitravatinib and nivolumab in clear cell renal cell carcinoma following progression on antiangiogenic therapy. Science translational medicine 14(641), 2022. PMID: 35442707.
82. Park Y, Liu S, Thall P, Yuan Y. Bayesian group sequential enrichment designs based on adaptive regression of response and survival time on baseline biomarkers. Biometrics 78(1):60-71, 2022. PMID: 33438761.
83. Mu R, Xu J, Tang RS, Kopetz S, Yuan Y. A Bayesian phase I/II platform design for co-developing drug combination therapies for multiple indications. Stat Med 41(2):374-389, 2022. e-Pub 2021. PMID: 34730248.
84. Garmezy B, Gheeya J, Lin HY, Huang Y, Kim T, Jiang X, Thein KZ, Pilié PG, Zeineddine F, Wang W, Shaw KR, Rodon J, Shen JP, Yuan Y, Meric-Bernstam F, Chen K, Yap TA. Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers. JCO Precis Oncol 6:e2100267, 2022. PMID: 35108036.
85. van Dijk LV, Frank SJ, Yuan Y, Gunn B, Moreno AC, Mohamed ASR, Preston KE, Qing Y, Spiotto MT, Morrison WH, Lee A, Phan J, Garden AS, Rosenthal DI, Langendijk JA, Fuller CD. Proton Image-guided Radiation Assignment for Therapeutic Escalation via Selection of locally advanced head and neck cancer patients [PIRATES]: A Phase I safety and feasibility trial of MRI-guided adaptive particle radiotherapy. Clin Transl Radiat Oncol 32:35-40, 2022. PMID: 34841093.
86. Scheurer, ME, Zhou, R, Gilbert, MR, Bondy, ML, Sulman, EP, Yuan, Y, Liu, Y, Vera, E, Wendland, MM, Youssef, E, Stieber, VW, Komaki, RR, Flickinger, J, Kenyon, LC, Robins, HI, Hunter, G, Crocker, I, Chao, ST, Pugh, S, Armstrong, TS. Germline polymorphisms in MGMT associated with temozolomide-related myelotoxicity risk in patients with glioblastoma treated on NRG Oncology/RTOG 0825. Neuro-Oncology Advances 4(1), 2022. PMID: 36299794.
87. Liu, R, Yuan, Y, Sen, S, Yang, X, Jiang, Q, Li, X, Lu, C, Gönen, M, Tian, H, Zhou, H, Lin, R, Marchenko, O. Accuracy and Safety of Novel Designs for Phase I Drug-Combination Oncology Trials. Statistics in Biopharmaceutical Research 14(3):270-282, 2022. PMID: 37275462.
88. Zhang, W, Pan, Z, Yuan, Y. A Bayesian group sequential design for randomized biosimilar clinical trials with adaptive information borrowing from historical data. Journal of Biopharmaceutical Statistics 32(3):359-372, 2022. PMID: 35679137.
89. Yuan Y, Chen K. Novel bayesian adaptive early phase designs to accelerate the development of CAR T-cell therapy. Hematology and Oncology Discovery 1(1):14-23, 2022. PMID: None.
90. Gross ND, Ferrarotto R, Amit M, Nagarajan P, Yuan Y, Bell D, Johnson JM, Morrison WH, Rosenthal DI, Glisson BS, Johnson FM, Mott F, Esmaeli B, Diaz E, Gidley P, Goepfert R, Lewis CM, Wargo JA, Weber RS, Myers J. Long-term outcomes of a phase II trial of neoadjuvant immunotherapy for advanced, resectable cutaneous squamous cell carcinoma of the head and neck (CSCC-HN). Journal of Clinical Oncology 40(None):Suppl:9519-9519, 2022. PMID: None.
91. Zhao Y, Yang B, Lee JJ, Yuan Y. Bayesian Optimal Phase II Design for Randomized Clinical Trials. Statistics in Biopharmaceutical Research, 2022. e-Pub 2022. PMID: None.
92. Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal RD, George TJ, Yuan Y, Yu L, Westin SN, Xing Y, Dumbrava EE, Karp DD, Piha-Paul SA, Tsimberidou AM, Ahnert JR, Takebe N, Lu K, Keyomarsi K, Meric-Bernstam F. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. Journal of Clinical Oncology, 2022. e-Pub 2022. PMID: None.
93. LinR, LiuR, ZhouH, YangX, YuanY, JiangQ, KeC, LiX, LuC, SenS, ̈onenM G, TianH, and Marchen O. Accuracy, Safety, and Risky Behavior of Novel Phase I Drug-Combination Trial Designs. Statistics in Biopharmaceutical Researc, 2022. e-Pub 2022. PMID: None.
94. Chaftari AM, Hachem R, Malek AE, Mulanovich VE, Szvalb AD, Jiang Y, Yuan Y, Ali S, Deeba R, Chaftari P, Raad I. A Prospective Randomized Study Comparing Ceftolozane/Tazobactam to Standard of Care in the Management of Neutropenia and Fever in Patients With Hematological Malignancies. Open Forum Infectious Diseases 9(6):ofac079, 2022. e-Pub 2022. PMID: None.
95. Carmack CL, Parker NH, Demark-Wahnefried W, Shely L, Baum G, Yuan Y, Giordano SH, Rodriguez-Bigas M, Pettaway C, Basen-Engquist K. Healthy Moves to Improve Lifestyle Behaviors of Cancer Survivors and Their Spouses: Feasibility and Preliminary Results of Intervention Efficacy. Nutrients 13(12), 2021. e-Pub 2021. PMID: 34960013.
96. Westin SN, Labrie M, Litton JK, Blucher A, Fang Y, Vellano CP, Marszalek JR, Feng N, Ma X, Creason A, Fellman B, Yuan Y, Lee S, Kim TB, Liu J, Chelariu-Raicu A, Chen TH, Kabil N, Soliman PT, Frumovitz M, Schmeler KM, Jazaeri A, Lu KH, Murthy R, Meyer LA, Sun CC, Sood AK, Coleman RL, Mills GB. Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clin Cancer Res 27(23):6354-6365, 2021. e-Pub 2021. PMID: 34518313.
97. Prokhorov AV, Calabro KS, Arya A, Russell S, Czerniak KW, Botello GC, Chen M, Yuan Y, Perez A, Vidrine DJ, Perry CL, Khalil GE. Mobile Text Messaging for Tobacco Risk Communication Among Young Adult Community College Students: Randomized Trial of Project Debunk. JMIR Mhealth Uhealth 9(11):e25618, 2021. e-Pub 2021. PMID: 34822339.
98. Melendez B, Shah S, Jiang Y, Dottino J, Watson E, Pearce H, Borthwick M, Schmandt RE, Zhang Q, Cumpian K, Celestino J, Fellman B, Yuan Y, Lu KH, Mikos AG, Yates MS. Novel polymer-based system for intrauterine delivery of everolimus for anti-cancer applications. J Control Release 339:521-530, 2021. e-Pub 2021. PMID: 34648891.
99. Phillips LM, Li S, Gumin J, Daou M, Ledbetter D, Yang J, Singh S, Parker Kerrigan BC, Hossain A, Yuan Y, Gomez-Manzano C, Fueyo J, Lang FF. An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus. Neuro Oncol 23(11):1911-1921, 2021. PMID: 34059921.
100. Zhou Y, Lee JJ, Wang S, Bailey S, Yuan Y. Incorporating historical information to improve phase I clinical trials. Pharm Stat 20(6):1017-1034, 2021. e-Pub 2021. PMID: 33793044.
101. Rutherford SC, Abramson JS, Bartlett NL, Barta SK, Khan N, Joyce R, Maddocks K, Ali-Shaw T, Senese S, Yuan Y, Westin J, Leonard JP. Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study. Lancet Haematol 8(11):e818-e827, 2021. e-Pub 2021. PMID: 34634256.
102. Zhang W, Pan Z, Yuan Y. Elastic meta-analytic-predictive prior for dynamically borrowing information from historical data with application to biosimilar clinical trials. Contemp Clin Trials 110:106559, 2021. e-Pub 2021. PMID: 34506959.
103. Pan J, Tan Y, Wang G, Deng B, Ling Z, Song W, Seery S, Zhang Y, Peng S, Xu J, Duan J, Wang Z, Yu X, Zheng Q, Xu X, Yuan Y, Yan F, Tian Z, Tang K, Zhang J, Chang AH, Feng X. Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial. J Clin Oncol 39(30):JCO2100389, 2021. e-Pub 2021. PMID: 34324392.
104. Patel RR, He K, Barsoumian HB, Chang JY, Tang C, Verma V, Comeaux N, Chun SG, Gandhi S, Truong MT, Erasmus JJ, Hong DS, Lee PP, Ning MS, Nguyen QN, Heymach JV, Altan M, Blumenschein G, Fossella FV, Sezen D, Chen D, Carter BW, Davies MA, Glitza IC, Diab A, Ferrarotto R, Cabanillas ME, Yuan Y, Shah SJ, Parra ER, Sun B, Cortez MA, Welsh JW. High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. Radiother Oncol 162:60-67, 2021. e-Pub 2021. PMID: 34237343.
105. Ferrarotto R, Amit M, Nagarajan P, Rubin ML, Yuan Y, Bell D, El-Naggar AK, Johnson JM, Morrison WH, Rosenthal DI, Glisson BS, Johnson FM, Lu C, Mott FE, Esmaeli B, Diaz EM, Gidley PW, Goepfert RP, Lewis CM, Weber RS, Wargo JA, Basu S, Duan F, Yadav SS, Sharma P, Allison JP, Myers JN, Gross ND. Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res 27(16):4557-4565, 2021. e-Pub 2021. PMID: 34187851.
106. Jiang L, Nie L, Yan F, Yuan Y. Optimal Bayesian hierarchical model to accelerate the development of tissue-agnostic drugs and basket trials. Contemp Clin Trials 107:106460, 2021. e-Pub 2021. PMID: 34098036.
107. Schipper MJ, Yuan Y, Taylor JM, Ten Haken RK, Tsien C, Lawrence TS. A Bayesian dose-finding design for outcomes evaluated with uncertainty. Clin Trials:17407745211001521. e-Pub 2021. PMID: 33884907.
108. Bahig H, Rosenthal DI, Nguyen-Tan FP, Fuller DC, Yuan Y, Hutcheson KA, Christopoulos A, Nichols AC, Fung K, Ballivy O, Filion E, Ng SP, Lambert L, Dorth J, Hu KS, Palma D. Vocal-cord Only vs. Complete Laryngeal radiation (VOCAL): a randomized multicentric Bayesian phase II trial. BMC Cancer 21(1):446, 2021. e-Pub 2021. PMID: 33888069.
109. Wu J, Yuan Y, Long Priel DA, Fink D, Peer CJ, Sissung TM, Su YT, Pang Y, Yu G, Butler MK, Mendoza TR, Vera E, Ahmad S, Bryla C, Lindsley M, Grajkowska E, Mentges K, Boris L, Antony R, Garren N, Siegel C, Lollo N, Cordova C, Aboud O, Theeler BJ, Burton EM, Penas-Prado M, Leeper H, Gonzales J, Armstrong TS, Calvo KR, Figg WD, Kuhns DB, Gallin JI, Gilbert MR. Phase I Study of Zotiraciclib in Combination with Temozolomide for Patients with Recurrent High-grade Astrocytomas. Clin Cancer Res. e-Pub 2021. PMID: 33785481.
110. Kang D, S Coffey C, J Smith B, Yuan Y, Shi Q, Yin J. Hierarchical Bayesian clustering design of multiple biomarker subgroups (HCOMBS). Stat Med. e-Pub 2021. PMID: 33772843.
111. Gilbert MR, Yuan Y, Wu J, Mendoza T, Vera E, Omuro A, Lieberman F, Robins HI, Gerstner ER, Wu J, Wen PY, Mikkelsen T, Aldape K, Armstrong TS. A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma. Neuro Oncol 23(3):468-477, 2021. e-Pub 2020. PMID: 33085768.
112. Jiang L, Li R, Yan F, Yap TA, Yuan Y. Shotgun: A Bayesian seamless phase I-II design to accelerate the development of targeted therapies and immunotherapy. Contemp Clin Trials 104:106338. e-Pub 2021. PMID: 33711459.
113. Shi H, Cao J, Yuan Y, Lin R. uTPI: A utility-based toxicity probability interval design for phase I/II dose-finding trials. Stat Med. e-Pub 2021. PMID: 33650708.
114. How JA, Jazaeri AA, Fellman B, Daniels MS, Penn S, Solimeno C, Yuan Y, Schmeler K, Lanchbury JS, Timms K, Lu KH, Yates MS. Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer. Cancers (Basel) 13(5), 2021. e-Pub 2021. PMID: 33668244.
115. Coleman RL, Hu W, Soliman P, Nick A, Ramirez PT, Westin SN, Garcia ME, Zhu Z, Palancia J, Fellman BM, Yuan Y, Ram P, Bischoff F, Schmeler K, Bodurka D, Meyer LA, Sood AK. Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. Gynecol Oncol. e-Pub 2021. PMID: 33551196.
116. Park Y, Yuan Y, Ning J, Liu S, Feng Z. Hybrid design evaluating new biomarkers when there is an existing screening test. Stat Med. e-Pub 2021. PMID: 33540472.
117. Park M, Liu S, Yap TA, Yuan Y. Evaluation of Deviation From Planned Cohort Size and Operating Characteristics of Phase 1 Trials. JAMA Netw Open 4(2):e2037563, 2021. e-Pub 2021. PMID: 33595664.
118. Majd NK, Mastall M, Lin H, Dibaj SS, Hess KR, Yuan Y, Garcia MM, Fuller GN, Alfaro KD, Gule-Monroe MK, Huse JT, Khatua S, Rao G, Sandberg DI, Wefel JS, Yeboa DN, Paulino AC, McGovern SL, Zaky W, Mahajan A, Suki D, Weathers SP, Harriso RA, De Groo JF, Puduvalli VK, Penas-Prado M. Clinical characterization of adult medulloblastoma and the effect of first-line therapies on outcome; The MD Anderson Cancer Center experience. Neurooncol Adv 3(1):vdab079, 2021. e-Pub 2021. PMID: 34377987.
119. Lin R, Thall PF, Yuan Y. BAGS: A Bayesian Adaptive Group Sequential Trial Design With Subgroup-Specific Survival Comparisons. J Am Stat Assoc 116(533):322-334, 2021. e-Pub 2020. PMID: 35582047.
120. Tidwell RSS, Thall PF, Yuan Y. Lessons Learned From Implementing a Novel Bayesian Adaptive Dose-Finding Design in Advanced Pancreatic Cancer. JCO Precis Oncol 5, 2021. e-Pub 2021. PMID: 34805718.
121. Jin IH, Zhang Z, Yuan Y. Social Network Mediation Analysis: a Latent Space Approach. Psychometrika 86:272–298, 2021. PMID: None.
122. Zhou Y, Li R, Yan F, Lee JJ, Yuan Y. A comparative study of Bayesian optimal interval (BOIN) design with interval 3+3 (i3+3) design for phase I oncology dose-finding trials. Statistics in Biopharmaceutical Research 13(2):147-155, 2021. PMID: None.
123. Walker JG, Armstrong TS, O'Brien BJ, Gilbert MR, Casarez RL, Fagundes C, Heijnen CJ, Andersen CR, Yuan Y, Wu J, LoBiondo-Wood G. Associations of meaning of illness with psychosocial, clinical, and immunological characteristics in patients with leptomeningeal metastasis. Comprehensive Psychoneuroendocrinology 8(None):100099, 2021. PMID: None.
124. Lin R, Thall P, Yuan Y. A Phase I-II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed Outcomes. Bayesian Analysis 16:179-202, 2021. PMID: None.
125. Hoffe S, Frakes JM, Aguilera TA, Czito B, Palta M, Brookes M, Schweizer C, Colbert L, Moningi S, Bhutani MS, Pant S, Tzeng CW, Tidwell RS, Thall P, Yuan Y, Moser EC, Holmlund J, Herman J, Taniguchi CM. Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in Combination with High Dose Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (PC). Int J Radiat Oncol Biol Phys 108(5):1399-1400, 2020. PMID: 33427657.
126. Lin R, Yang Z, Yuan Y, Yin G. Sample size re-estimation in adaptive enrichment design. Contemp Clin Trials:106216. e-Pub 2020. PMID: 33246098.
127. Yin J, Yuan Y. Checkerboard: a Bayesian efficacy and toxicity interval design for phase I/II dose-finding trials. J Biopharm Stat:1-20. e-Pub 2020. PMID: 32966167.
128. Atkins JT, George GC, Hess K, Marcelo-Lewis KL, Yuan Y, Borthakur G, Khozin S, LoRusso P, Hong DS. Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials. Br J Cancer 123(10):1496-1501. e-Pub 2020. PMID: 32868897.
129. Dottino JA, Zhang Q, Loose DS, Fellman B, Melendez BD, Waters MS, McKenzie LJ, Yuan Y, Yang RK, Broaddus RR, Lu KH, Soliman PT, Yates MS. Endometrial biomarkers in premenopausal obese women: an at-risk cohort. Am J Obstet Gynecol 9378(20):30881-30884. e-Pub 2020. PMID: 32835719.
130. Westin SN, Fellman B, Sun CC, Broaddus RR, Woodall ML, Pal N, Urbauer DL, Ramondetta LM, Schmeler KM, Soliman PT, Fleming ND, Burzawa JK, Nick AM, Milbourne AM, Yuan Y, Lu KH, Bodurka DC, Coleman RL, Yates MS. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol S0002-9378(20):30861-308619. e-Pub 2020. PMID: 32805208.
131. Abi Jaoude J, Kouzy R, Minsky BD, Fuller CD, Yuan Y, Do KA, Taniguchi CM, Ludmir EB. Sponsor-involved statistical analyses in Phase III cancer clinical trials. Int J Cancer 147(12):3579-3581. e-Pub 2020. PMID: 32621758.
132. Zhou H, Chen C, Sun L, Yuan Y. Bayesian optimal phase II clinical trial design with time-to-event endpoint. Pharm Stat(19):776-786. e-Pub 2020. PMID: 32524679.
133. de Groot J, Penas-Prado M, Alfaro-Munoz K, Hunter K, Pei BL, O'Brien B, Weathers SP, Loghin M, Kamiya Matsouka C, Yung WKA, Mandel J, Wu J, Yuan Y, Zhou S, Fuller GN, Huse J, Rao G, Weinberg JS, Prabhu SS, McCutcheon IE, Lang FF, Ferguson SD, Sawaya R, Colen R, Yadav SS, Blando J, Vence L, Allison J, Sharma P, Heimberger AB. Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol 22(4):539-549, 2020. PMID: 31755915.
134. Pan H, Cheng C, Yuan Y. Bayesian adaptive linearization method for phase I drug combination trials with dimension reduction. Pharm Stat. e-Pub 2020. PMID: 32248647.
135. Puduvalli VK, Wu J, Yuan Y, Armstrong TS, Vera E, Wu J, Xu J, Giglio P, Colman H, Walbert T, Raizer J, Groves MD, Tran D, Iwamoto F, Avgeropoulos N, Paleologos N, Fink K, Peereboom D, Chamberlain M, Merrell R, Penas Prado M, Yung WKA, Gilbert MR. A Bayesian Adaptive Randomized Phase II Multicenter Trial of Bevacizumab with or without Vorinostat in Adults with Recurrent Glioblastoma. Neuro Oncol. e-Pub 2020. PMID: 32166308.
136. Pan H, Lin R, Zhou Y, Yuan Y. Keyboard design for phase I drug-combination trials. Contemp Clin Trials(92):105972. e-Pub 2020. PMID: 32151751.
137. Shin SJ, Dodd-Eaton EB, Peng G, Bojadzieva J, Chen J, Amos CI, Frone MN, Khincha PP, Mai PL, Savage SA, Ballinger ML, Thomas DM, Yuan Y, Strong LC, Wang W. Penetrance of Different Cancer Types in Families with Li-Fraumeni Syndrome: A Validation Study Using Multicenter Cohorts. Cancer Res 80(2):354-360, 2020. e-Pub 2019. PMID: 31719101.
138. Palermo TM, Murray C, Aalfs H, Abu-El-Haija M, Barth B, Bellin MD, Ellery K, Fishman DS, Gariepy CE, Giefer MJ, Goday P, Gonska T, Heyman MB, Husain SZ, Lin TK, Liu QY, Mascarenhas MR, Maqbool A, McFerron B, Morinville VD, Nathan JD, Ooi CY, Perito ER, Pohl JF, Schwarzenberg SJ, Sellers ZM, Serrano J, Shah U, Troendle D, Zheng Y, Yuan Y, Lowe M, Uc A, Chronic Pancreatitis CFTSO, Diabetes, Cancer P. Web-based cognitive-behavioral intervention for pain in pediatric acute recurrent and chronic pancreatitis: Protocol of a multicenter randomized controlled trial from the study of chronic pancreatitis, diabetes and pancreatic cancer (CPDPC). Contemp Clin Trials 88:105898, 2020. e-Pub 2019. PMID: 31756383.
139. Li Y, Yuan Y. PA-CRM: A Continuous Reassessment Method for Pediatric Phase I Oncol-ogy Trials with Concurrent Adult Trials. Biometrics, 2020. PMID: None.
140. Lin R, Zhou Y, Yan F, Li D, Yuan Y. BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies. JCO Precis Oncol 4, 2020. e-Pub 2020. PMID: 33283133.
141. Han Y, Yuan Y, Cao S, Li M, Zang Y. On the Use of Marker Strategy Design to Detect Predictive Marker Effect in Cancer Immunotherapy. Statistics in Biosciences(12):180195, 2020. PMID: None.
142. Zhou Y, Li R, Kuo Y, Lee JJ, Yuan Y. BOIN Suite: a software platform to design and implement novel early phase clinical trials. JCO Clinical Cancer Informatics, 2020. PMID: None.
143. Yan F, Pan H, Zhang L, Liu S, Yuan Y. BOIN: An R Package for Designing Single- Agent and Drug-Combination Dose-Finding Trials Using Bayesian Optimal Interval Designs. Journal of Statistical Software 94(13):1-32, 2020. PMID: None.
144. Zhou Y, Lee JJ, Yuan Y. A utility-based Bayesian optimal interval (U-BOIN) phase I/II design to identify the optimal biological dose for targeted and immune therapies. Stat Med 38(28):5299-5316, 2019. e-Pub 2019. PMID: 31621952.
145. Tidwell RSS, Peng SA, Chen M, Liu DD, Yuan Y, Lee JJ. Bayesian clinical trials at The University of Texas MD Anderson Cancer Center: An update. Clin Trials 16(6):645-656, 2019. e-Pub 2019. PMID: 31450957.
146. Jiang H, Shin DH, Nguyen TT, Fueyo J, Fan X, Henry V, Carrillo CC, Yi Y, Alonso MM, Collier TL, Yuan Y, Lang FF, Gomez-Manzano C. Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas. Clin Cancer Res 25(22):6801-6814, 2019. e-Pub 2019. PMID: 31455679.
147. Soliman PT, Westin SN, Iglesias DA, Fellman BM, Yuan Y, Zhang Q, Yates MS, Broaddus RR, Slomovitz BM, Lu KH, Coleman RL. Everolimus, Letrozole, and Metformin in Women with Advanced or Recurrent Endometrioid Endometrial Cancer: A Multi-Center, Single Arm, Phase II Study. Clin Cancer Res 26(3):581-587. e-Pub 2019. PMID: 31628143.
148. Lin R, Thall PF, Yuan Y. An adaptive trial design to optimize dose-schedule regimes with delayed outcomes. Biometrics 76(1):304-315. e-Pub 2019. PMID: 31273750.
149. Yan F, Thall P, Yuan Y. One-Year Outcomes after PCI Strategies in Cardiogenic Shock. N Engl J Med 380(19):1876-1877, 2019. PMID: 31067386.
150. Harrison RA, Anderson MD, Cachia D, Kamiya-Matsuoka C, Weathers SS, O'Brien BJ, Penas-Prado M, Yung WKA, Wu J, Yuan Y, de Groot JF. Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center. Eur J Cancer 112:83-93, 2019. e-Pub 2019. PMID: 30951926.
151. Lin R, Yuan Y. Time-to-event model-assisted designs for dose-finding trials with delayed toxicity. Biostatistics 21(4):807-824. e-Pub 2019. PMID: 30984972.
152. Tang R, Shen J, Yuan Y. ComPAS: A Bayesian drug combination platform trial design with adaptive shrinkage. Stat Med 38(7):1120-1134, 2019. e-Pub 2018. PMID: 30419609.
153. Lin R, Coleman RL, Yuan Y. TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy. J Natl Cancer Inst 112(1):38-45. e-Pub 2019. PMID: 30924863.
154. Mu R, Yuan Y, Xu J, Mandrekar SJ, Jun Y. gBOIN: A unified phase I trial design accounting for toxicity grades. Journal of the Royal Statistical Society: Series C 68:289-308, 2019. PMID: None.
155. Huang J, Yuan Y, Wetter D. Latent Class Dynamic Mediation Model with Application to Smoking Cessation Data. Psychometrika 84(1):1-18. e-Pub 2019. PMID: 30607659.
156. Shin SJ, Yuan Y, Strong LC, Bojadzieva J, Wang W. Bayesian Semiparametric Estimation of Cancer-specific Age-at-onset Penetrance with Application to Li-Fraumeni Syndrome. J Am Stat Assoc 114(526):541-552, 2019. e-Pub 2018. PMID: 31485091.
157. Ursino M, Yuan Y, Comets E, Favrais G, Friede T, Lentz F, Stallard N, Zohar S. A dose-finding design for seizure reduction in neonates. Journal of the Royal Statistical Society: Series C 68(2):427-444, 2019. PMID: None.
158. Zhang C, Martinez-Ledesma E, Gao F, Zhang W, Ding J, Wu S, Li X, Wu J, Yuan Y, Koul D, Alfred Yung WK. Wild-type TP53 defined gamma-secretase inhibitor sensitivity and synergistic activity with doxorubicin in GSCs. Am J Cancer Res 9(8):1734-1745, 2019. e-Pub 2019. PMID: 31497354.
159. Vidrine DJ, Frank-Pearce SG, Vidrine JI, Tahay PD, Marani SK, Chen S, Yuan Y, Cantor SB, Prokhorov AV. Efficacy of Mobile Phone Delivered Smoking Cessation Interventions for Socioeconomically Disadvantaged Individuals: A randomized controlled trial. JAMA Internal Medicine 179(2):167-174, 2019. PMID: None.
160. Lin R, Yuan Y. On the Relative Efficiency of Model-Assisted Designs: A Conditional Approach. J Biopharm Stat 29(4):648-662, 2019. e-Pub 2019. PMID: 31258039.
161. Ahn, J, Morita, S, Wang W, Yuan, Y. Bayesian Shared Parameter Models for Dyadic Longitudinal Data with Informative Missing Data. Statistical Methods in Medical Research 28(1):70-83, 2019. PMID: None.
162. Vidrine DJ, Frank-Pearce SG, Vidrine JI, Tahay PD, Marani SK, Chen S, Yuan Y, Cantor SB, Prokhorov AV. Efficacy of Mobile Phone-Delivered Smoking Cessation Interventions for Socioeconomically Disadvantaged Individuals: A Randomized Clinical Trial. JAMA Intern Med. e-Pub 2018. PMID: 30556832.
163. Uc A, Perito ER, Pohl JF, Shah U, Abu-El-Haija M, Barth B, Bellin MD, Ellery KM, Fishman DS, Gariepy CE, Giefer MJ, Gonska T, Heyman MB, Himes RW, Husain SZ, Maqbool A, Mascarenhas MR, McFerron BA, Morinville VD, Lin TK, Liu QY, Nathan JD, Rhee SJ, Ooi CY, Sellers ZM, Schwarzenberg SJ, Serrano J, Troendle DM, Werlin SL, Wilschanski M, Zheng Y, Yuan Y, Lowe ME. INternational Study Group of Pediatric Pancreatitis: In Search for a CuRE Cohort Study: Design and Rationale for INSPPIRE 2 From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer. Pancreas 47(10):1222-1228, 2018. PMID: 30325861.
164. Bahig H, Yuan Y, Mohamed ASR, Brock KK, Ng SP, Wang J, Ding Y, Hutcheson K, McCulloch M, Balter PA, Lai SY, Al-Mamgani A, Sonke JJ, van der Heide UA, Nutting C, Li XA, Robbins J, Awan M, Karam I, Newbold K, Harrington K, Oelfke U, Bhide S, Philippens MEP, Terhaard CHJ, McPartlin AJ, Blanchard P, Garden AS, Rosenthal DI, Gunn GB, Phan J, Cazoulat G, Aristophanous M, McSpadden KK, Garcia JA, van den Berg CAT, Raaijmakers CPJ, Kerkmeijer L, Doornaert P, Blinde S, Frank SJ, Fuller CD. Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial. Clin Transl Radiat Oncol 13(None):19-23, 2018. PMID: 30386824.
165. Hart PA, Andersen DK, Mather KJ, Castonguay AC, Bajaj M, Bellin MD, Bradley D, Contreras N, Habtezion A, Korc M, Kudva Y, Petrov MS, Whitcomb DC, Yadav D, Yuan Y, Rinaudo JAS, Srivastava S, Serrano J, Goodarzi MO. Evaluation of a Mixed Meal Test for Diagnosis and Characterization of PancrEaTogEniC DiabeTes Secondary to Pancreatic Cancer and Chronic Pancreatitis: Rationale and Methodology for the DETECT Study From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer. Pancreas 47(10):1239-1243, 2018. PMID: 30325863.
166. Guo B, Li D, Yuan Y. SPIRIT: A seamless phase I/II randomized design for immunotherapy trials. Pharm Stat 17(5):527-540, 2018. e-Pub 2018. PMID: 29882388.
167. Ng SP, Bahig H, Wang J, Cardenas CE, Lucci A, Hall CS, Meas S, Sarli VN, Yuan Y, Urbauer DL, Ding Y, Ikner S, Dinh V, Elgohari BA, Johnson JM, Skinner HD, Gunn GB, Garden AS, Phan J, Rosenthal DI, Morrison WH, Frank SJ, Hutcheson KA, Mohamed ASR, Lai SY, Ferrarotto R, MacManus MP, Fuller CD. Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching 'liquid biopsy' and quantitative tumor modeling. BMC Cancer 18(1):903, 2018. e-Pub 2018. PMID: 30231854.
168. Zhou H, Yuan Y, Nie L. Accuracy, Safety, and Reliability of Novel Phase I Trial Designs. Clinical Cancer Research 24(18):4357-4364, 2018. e-Pub 2018. PMID: 29661774.
169. Yates MS, Coletta AM, Zhang Q, Schmandt RE, Medepalli M, Nebgen D, Soletsky B, Milbourne A, Levy E, Fellman B, Urbauer D, Yuan Y, Broaddus RR, Basen-Engquist K, Lu K. Prospective Randomized Biomarker Study of Metformin and Lifestyle Intervention for Prevention in Obese Women at Increased Risk for Endometrial Cancer. Cancer Prevention Research (Phila) 11(8):477-490, 2018. e-Pub 2018. PMID: 29716897.
170. Zhou H, Murray TA, Pan H, Yuan Y. Comparative review of novel model-assisted designs for phase I clinical trials. Stat Med 37(14):2208-2222, 2018. e-Pub 2018. PMID: 29682777.
171. Arvold N, Armstrong T, Warren K, Blakeley J, DeAngelis LM, Chamberlain MC, Chang SM, Dunbar E, Loong H, Macdonald D, Reardon DA, Vogelbaum M, Wheeler HR, Yuan Y, Weller M, Van Den Bent M, Wen PY. Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology (RANO) Working Group. Neuro-Oncology 20(7):897-906, 2018. PMID: 29788429.
172. Chu Y, Yuan Y. A Bayesian basket trial design using a calibrated Bayesian hierarchical model. Clinical Trials 15(2):149-158, 2018. e-Pub 2018. PMID: 29499621.
173. Pan H, Liu S, Miao D, Yuan Y. Sample size determination for mediation analysis of longitudinal data. BMC Med Res Methodol 18(1):32, 2018. e-Pub 2018. PMID: 29580203.
174. Shen W, Ning J, Yuan Y, Lok AS, Feng Z. Model-free scoring system for risk prediction with application to hepatocellular carcinoma study. Biometrics 74(1):239-248, 2018. e-Pub 2017. PMID: 28742219.
175. Riviere MK, Yuan Y, Jourdan JH, Dubois F, Zohar S. Phase I/II dose-finding design for molecularly targeted agent: Plateau determination using adaptize randomization. Stat Methods Med Res 27(2):466-479, 2018. e-Pub 2016. PMID: 26988926.
176. Mandel JJ, Yust-Katz S, Patel AJ, Cachia D, Liu D, Park M, Yuan Y, Kent TA, de Groot JF. Inability of positive phase II clinical trials of investigational treatments to subsequently predict positive phase III clinical trials in glioblastoma. Neuro Oncol 20(1):113-122, 2018. e-Pub 2017. PMID: 29016865.
177. Yan F, Thall PF, Lu KH, Gilbert MR, Yuan Y. Phase I-II clinical trial design: A state-of-the-art paradigm for dose finding with novel agents. Annals of Oncology 29:694-699, 2018. PMID: None.
178. Chu Y, Yuan Y. BLAST: Bayesian Latent Subgroup Design for Basket Trials Accounting for Patient Heterogeneity. Journal of the Royal Statistical Society: Series C 67:723-740, 2018. PMID: None.
179. Liu S, Guo B, Yuan Y. A Bayesian Phase I/II Design for Immunotherapy Trials. Journal of American Statistical Association 113:1016-1027, 2018. e-Pub 2017. PMID: None.
180. Yuan Y, Lin R, Li D, Nie L, Warren KE. Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials. Clin Cancer Res 24:4921-4930, 2018. e-Pub 2018. PMID: 29769209.
181. Murray T, Thall P, Yuan Y. A Bayesian Machine Learning Method for Optimizing Dynamic Treatment Regimes. Journal of the American Statistical Association 113:1255-1267, 2018. PMID: None.
182. Murray T, Yuan Y, Thall P, Elizondo JH, Hofstetter W. A Bayesian Utility-Based Stratified Medicine Design for the Effectiveness of Nutritional Prehabilitation in Thoracic Surgery. Biometrics 74:1095-1103, 2018. PMID: None.
183. Pan H, Yuan Y, Xia J. A Calibrated Power Prior Approach to Borrow Information from Historical Data with Application to Biosimilar Clinical Trials. J R Stat Soc Ser C Appl Stat 66(5):979-996, 2017. e-Pub 2016. PMID: 29249839.
184. Zhou H, Lee JJ, Yuan Y. BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints. Stat Med 36(21):3302-3314, 2017. e-Pub 2017. PMID: 28589563.
185. Cai C, Rahbar MH, Hossain MM, Yuan Y, Gonzales NR. A placebo-controlled Bayesian dose finding design based on continuous reassessment method with application to stroke research. Contemp Clin Trials Commun 7:11-17, 2017. e-Pub 2017. PMID: 29062975.
186. Yan F, Mandrekar SJ, Yuan Y. Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials. Clin Cancer Res 23(15):3994-4003, 2017. e-Pub 2017. PMID: 28546227.
187. Pakish JB, Zhang Q, Chen Z, Liang H, Chisholm GB, Yuan Y, Mok SC, Broaddus RR, Lu KH, Yates MS. Immune Microenvironment in Microsatellite-Instable Endometrial Cancers: Hereditary or Sporadic Origin Matters. Clin Cancer Res 23(15):4473-4481, 2017. e-Pub 2017. PMID: 28264871.
188. Harano K, Kogawa T, Wu J, Yuan Y, Cohen EN, Lim B, Reuben JM, Ueno NT. Thrombocytosis as a prognostic factor in inflammatory breast cancer. Breast Cancer Res Treat. e-Pub 2017. PMID: 28831670.
189. Jiang H, Rivera-Molina Y, Gomez-Manzano C, Clise-Dwyer K, Bover L, Vence LM, Yuan Y, Lang FF, Toniatti C, Hossain MB, Fueyo J. Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination. Cancer Res 77(14):3894-3907, 2017. e-Pub 2017. PMID: 28566332.
190. Pan H, Yuan Y. A Default Method to Specify Skeletons for Bayesian Model Averaging Continual Reassessment Method for Phase I Clinical Trials. Stat Med 36(2):266-279, 2017. e-Pub 2016. PMID: 26991076.
191. Ahn J, Morita S, Wang W, Yuan Y. Bayesian analysis of longitudinal dyadic data with informative missing data using a dyadic shared-parameter model. Stat Methods Med Res:962280217715051. e-Pub 2017. PMID: 28629259.
192. Huang J, Yuan Y. Bayesian Dynamic Mediation Analysis. Psychological Methods 22(4):667-686, 2017. PMID: None.
193. Katz L, Advani S, Burton-Chase AM, Fellman B, Polivka KM, Yuan Y, Lynch PM, Peterson SK. Cancer Screening Behaviors and Risk Perceptions among Family Members of Colorectal Cancer Patients with Lynch-Like Syndrome. Familial Cancer 16:231-237, 2017. PMID: None.
194. Murray TA, Thall PF, Yuan Y, McAvoy S, Gomez DR. Robust treatment comparison based on utilities of semi-competing risks in non-small-cell lung cancer. J Am Stat Assoc 112:11-23, 2017. e-Pub 2017. PMID: 28943681.
195. Chen Z, Li Z, Zhuang R, Yuan Y, Kutner M, Owonikoko T, Curran WJ, Kowalski J. Adaptive estimation of personalized maximum tolerated dose in cancer phase I clinical trials based on all toxicities and individual genomic profile,. PLoS One 12(1):e0170187, 2017. e-Pub 2017. PMID: 28125617.
196. Yuan Y, Qiu H, Hu XY, Luo T, Gao XJ, Zhao XY, Zhang J, Wu Y, Yan HB, Qiao SB, Yang YJ, Gao RL. Risk Factors of Contrast-induced Acute Kidney Injury in Patients Undergoing Emergency Percutaneous Coronary Intervention. Chin Med J (Engl) 130(1):45-50, 2017. PMID: 28051022.
197. Yuan Y, Guo B, Munsell M, Lu K, Jazzari A. MIDAS: a practical Bayesian design for platform trials with molecularly targeted agents. Statistics in Medicine 35(22):3892-906, 2016. PMID: 27112322.
198. Zang Y, Yuan Y. Optimal sequential enrichment designs for phase II clinical trials. Stat Med 36:54-66, 2016. PMID: 27640874.
199. Yuan Y, Hess K, Hilsenbeck S, Gilbert M. Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials. Clinical Cancer Research 22(17):4291-301, 2016. PMID: 27407096.
200. Iasonos A, Wages NA, Conaway MR, Cheung K, Yuan Y, O'Quigley J. Dimension of model parameter space and operating characteristics in adaptive dose-finding studies. Stat Med 354(21):3760-75, 2016. PMID: 27090197.
201. Chu Y, Pan H, Yuan Y. Adaptive dose modification for phase I clinical trials Third place winner in Biopharmaceutical Section Student Paper Award of JSM 2016. Statictics in Medicine 35(20):3497-508, 2016. PMID: 27027650.
202. Guo B, Yuan Y. Bayesian Phase I/II Biomarker-based Dose Finding for Precision Medicine with Molecularly Targeted Agents. Journal of American Statistical Association 112:508-520. e-Pub 2016. PMID: None.
203. Zhang, L, Yuan, Y. A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials. Stat Med 35:4924-4936, 2016. PMID: 27580928.
204. Zang Y, Liu S, Yuan Y. Optimal Marker-strategy Clinical Trial Design to Detect Predictive Markers for Targeted Therapy. Biostatistics 3:549-60, 2016. PMID: 26951724.
205. Zhang L, Yuan Y, Lu K, Zhang L. Identification of recurrent focal copy number variations and their putative targeted driver genes in ovarian cancer. BMC Bioinformatics 17(1):222, 2016. PMID: 27230211.
206. Murray T, Thall P, Yuan Y. Utility-Based Designs for Randomized Comparative Trials with Categorical Outcomes. Statictics in Medicine 35(24):4285-4305, 2016. PMID: 27189672.
207. Hamza MA, Kamiya-Matsuoka C, Liu D, Yuan Y, Puduvalli VK. Outcome of patients with malignant glioma and synchronous or metachronous non-central nervous system primary neoplasms. J Neurooncol 126(3):527-33, 2016. e-Pub 2015. PMID: 26566652.
208. Zang Y, Lee J, Yuan Y. Two-stage marker-stratified clinical trial design in the presence of biomarker misclassification. Journal of the Royal Statistical Society: Series C 65:585-601, 2016. PMID: None.
209. Katz LH, Burton-Chase AM, Advani S, Fellman B, Polivka KM, Yuan Y, Lynch PM, Peterson SK. Screening adherence and cancer risk perceptions in colorectal cancer survivors with Lynch-like syndrome. Clin Genet 89:392-398, 2016. e-Pub 2015. PMID: 26272410.
210. Raizer JJ, Giglio P, Hu J, Groves M, Merrell R, Conrad C, Phuphanich S, Puduvalli VK, Loghin M, Paleologos N, Yuan Y, Liu D, Rademaker A, Yung WK, Vaillant B, Rudnick J, Chamberlain M, Vick N, Grimm S, Tremont-Lukats IW, De Groot J, Aldape K, Gilbert MR, Trials Collaborative BT. A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients. J Neurooncol 126:185-192, 2016. e-Pub 2015. PMID: 26476729.
211. Guo B, Li Y, Yuan Y. A dose-schedule-finding design for phase I/II clinical trials. Journal of the Royal Statistical Society, Series C 65:259-272, 2016. PMID: 26877554.
212. Jin IH, Yuan Y, Bandyopadhyay D. A Bayesian hierarchical spatial model for dental caries assessment using non-gaussian markov random fields. Ann Appl Stat 10(2):884-905, 2016. e-Pub 2016. PMID: 27807470.
213. Shen W, Ning J, Yuan Y. Rate-adaptive Bayesian indpendent component analysis. Electronic Journal of Statistics 10:3247-3264, 2016. PMID: None.
214. Katz LH, Advani S, Burton-Chase AM, Fellman B, Polivka KM, Yuan Y. Cancer Screening Behaviors and Risk Perceptions among Family Members of Colorectal Cancer Patients with Lynch-Like Syndrome. Clinical Genetics 89:392-398, 2016. PMID: None.
215. Zang Y, Liu S, Yuan Y. Optimal Marker-Adaptive Designs for Target Therapy Based on Imperfectly Measured Biomarkers. Journal of the Royal Statistical Society: Series C 64(4):635-650, 2015. PMID: None.
216. Armstrong TS, Yuan Y, Wu J, Acquaye AA, Vera-Bolanos E, Gilbert MR, Brown PD, Vardy J, Chung C. The relationship between corticosteroids and symptoms in patients with primary brain tumors: utility of the Dexamethasone Symptom Questionnaire-Chronic. Neuro Oncol 17(8):1114-20, 2015. e-Pub 2015. PMID: 25862766.
217. Yust-Katz S, Mandel JJ, Wu J, Yuan Y, Webre C, Pawar TA, Lhadha HS, Gilbert MR, Armstrong TS. Venous thromboembolism (VTE) and glioblastoma. J Neurooncol 124(1):87-94, 2015. e-Pub 2015. PMID: 25985958.
218. Shen W, Ning J, Yuan Y. A Direct Method to Evaluate the Time-dependent Predictive Accuracy for Biomarkers. Biometrics 71(2):439-49, 2015. e-Pub 2015. PMID: 25758584.
219. Gong AH, Wei P, Zhang S, Yao J, Yuan Y, Zhou AD, Lang FF, Heimberger AB, Rao G, Huang S. FoxM1 Drives a Feed-Forward STAT3-Activation Signaling Loop That Promotes the Self-Renewal and Tumorigenicity of Glioblastoma Stem-like Cells. Cancer Res 75(11):2337-48, 2015. e-Pub 2015. PMID: 25832656.
220. Shen W, Ning J, Yuan Y. Bayesian sequential monitoring design for two-arm randomized clinical trials with noncompliance. Stat Med 34(13):2104-15, 2015. e-Pub 2015. PMID: 25756852.
221. Liu S, Pan H, Xia J, Huang Q, Yuan Y. Bridging continual reassessment method for phase I clinical trials in different ethnic populations. Stat Med 34(10):1681-94, 2015. e-Pub 2015. PMID: 25626429.
222. Chen Z, Yuan Y, Li Z, Kutner M, Owonikoko T, Curran WJ, Khuri F, Kowalski J. Dose escalation with over-dose and under-dose controls in Phase I/II clinical trials. Contemp Clin Trials 43:133-141. e-Pub 2015. PMID: 26012358.
223. DeWire M, Fouladi M, Turner DC, Wetmore C, Hawkins C, Jacobs C, Yuan Y, Liu D, Goldman S, Fisher P, Rytting M, Bouffet E, Khakoo Y, Hwang EI, Foreman N, Stewart CF, Gilbert MR, Gilbertson R, Gajjar A. An open-label, two-stage, phase II study of bevacizumab and lapatinib in children with recurrent or refractory ependymoma: a collaborative ependymoma research network study (CERN). J Neurooncol 17(8):1114-1120, 2015. e-Pub 2015. PMID: 25859842.
224. Guo B, Yuan Y. A Bayesian dose-finding design for phase I/II clinical trials with nonignorable dropouts. Stat Med 34(10):1721-32, 2015. e-Pub 2015. PMID: 25626676.
225. Olar A, Wani KM, Alfaro-Munoz KD, Heathcock LE, van Thuijl HF, Gilbert MR, Armstrong TS, Sulman EP, Cahill DP, Vera-Bolanos E, Yuan Y, Reijneveld JC, Ylstra B, Wesseling P, Aldape KD. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. Acta Neuropathol 129(4):585-96, 2015. e-Pub 2015. PMID: 25701198.
226. Vera-Bolanos E, Aldape K, Yuan Y, Wu J, Wani K, Necesito-Reyes MJ, Colman H, Dhall G, Lieberman FS, Metellus P, Mikkelsen T, Omuro A, Partap S, Prados M, Robins HI, Soffietti R, Wu J, Gilbert MR, Armstrong TS, Foundation C. Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. Neuro Oncol 17(3):440-7, 2015. e-Pub 2014. PMID: 25121770.
227. Jin IH, Huo L, Yin G, Yuan Y. Phase I trial design for drug combinations with Bayesian model averaging. Pharm Stat 14(2):108-19, 2015. e-Pub 2015. PMID: 25641851.
228. Guo B, Zang Y, Yuan, Y. A Bayesian Phase I/II Clinical Trial Design in the Presence of Informative Dropouts. Statistics and Its Interface 8:217-226, 2015. e-Pub 2015. PMID: None.
229. Fellman B, Yuan Y. Bayesian Optimal Interval Designs for Phase I Clinical Trials. The Stata Journal 15(1):110-120, 2015. PMID: None.
230. Riviere MK, Yuan Y, Dubois F, Zohar S. A Bayesian Dose-finding Design for Clinical Trials Combining a Cytotoxic Agent with a Molecularly Targeted Agent. Journal of the Royal Statistical Society, Series C 64:215-229, 2015. PMID: None.
231. Jiang Y, Malouf GG, Zhang J, Zheng X, Chen Y, Thompson EJ, Weinstein JN, Yuan Y, Spano JP, Broaddus R, Tannir NM, Khayat D, Lu KH, Su X. Long non-coding RNA profiling links subgroup classification of endometrioid endometrial carcinomas with trithorax and polycomb complex aberrations. Oncotarget 6:39865-39876, 2015. e-Pub 2015. PMID: 26431491.
232. Liu S, Yuan Y. Bayesian Optimal Interval Designs for Phase I Clinical Trials. Journal of the Royal Statistical Society: Series C 64:507-523, 2015. PMID: None.
233. Zang Y, Liu S, Yuan Y. Optimal marker-adaptive designs for targeted therapy based on imperfectly measured biomarkers. Journal of the Royal Statistical Society: Series C 64:507-523, 2015. PMID: None.
234. Malouf GG, Zhang J, Yuan Y, Compérat E, Rouprêt M, Cussenot O, Chen Y, Thompson EJ, Tannir NM, Weinstein JN, Valero V, Khayat D, Spano JP, Su X. Characterization of IncRna transcriptome in dlear-cell renal cell carcinoma by next-generation deep sequencing. Mol Oncol 9:32-43, 2015. e-Pub 2014. PMID: 25126716.
235. Cai C, Liu S, Yuan Y. A Bayesian Design for Phase II Clinical Trials with Delayed Responses Based on Multiple Imputation. Stat Med 33(23):4017-28, 2014. e-Pub 2014. PMID: 24817556.
236. Riviere MK, Yuan Y, Dubois F, Zohar S. A Bayesian dose-finding design for drug combination clinical trials based on the logistic model. Pharm Stat 13(4):247-57, 2014. e-Pub 2014. PMID: 24828456.
237. Liu S, Yuan Y, Castillo R, Guerrero T, Johnson VE. Evaluation of image registration spatial accuracy using a Bayesian hierarchical model. Biometrics 70(2):366-77, 2014. e-Pub 2014. PMID: 24575781.
238. Zang Y, Lee JJ, Y Y. Adaptive Designs for Identifying Optimal Biological Dose for Molecularly Targeted Agents. Clin Trials 11(3):319-327. e-Pub 2014. PMID: 24844841.
239. Hong J, Yuan Y, Wang J, Liao Y, Zou R, Zhu C, Li B, Liang Y, Huang P, Wang Z, Lin W, Zeng Y, Dai JL, Chung RT. Expression of variant isoforms of the tyrosine kinase SYK determines the prognosis of hepatocellular carcinoma. Cancer Res 74(6):1845-56, 2014. e-Pub 2014. PMID: 24477596.
240. Yust-Katz S, Anderson MD, Liu D, Wu J, Yuan Y, Olar A, Fuller GN, Brown PD, de-Groot JF. Clinical and prognostic features of adult patients with gangliogliomas. Neuro Oncol 16(3):409-13, 2014. e-Pub 2013. PMID: 24305706.
241. Yuan Y, Mackinnon DP. Robust Mediation Analysis Based on Median Regression. Psychol Methods 19(1):1-20, 2014. e-Pub 2013. PMID: 24079925.
242. Saito N, Fu J, Zheng S, Yao J, Wang S, Liu DD, Yuan Y, Sulman EP, Lang FF, Colman H, Verhaak RG, Yung WK, Koul D. A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor initiating cells. Stem Cells 32(1):301-12, 2014. e-Pub 2013. PMID: 24038660.
243. Cai C, Yuan Y, Ji Y. A Bayesian Dose-finding Design for Oncology Clinical Trials of Combinational Biological Agents. J R Stat Soc Ser C Appl Stat 63(1):159-173, 2014. PMID: 24511160.
244. Cai C, Yuan Y, Ji Y. Bayesian Phase I/II Design for Oncology Clinical Trials of Combining Biological Agents. Journal of the Royal Statistical Society: Series C 63:159-173, 2014. PMID: None.
245. Jin IH, Liu S, Thall PF, Yuan Y. Using data augmentation to facilitate conduct of phase I/II clinical trials with delayed outcomes. J Am Stat Assoc 109(506):525-536, 2014. PMID: 25382884.
246. Yust-Katz S, de Groot JF, Liu D, Wu J, Yuan Y, Anderson MD, Conrad CA, Milbourne A, Gilbert MR, Armstrong TS. Pregnancy and Glial brain tumors. Neuro-Oncology 16:1289-1294, 2014. PMID: None.
247. Castillo SJ, Castillo R, Balter P, Pan T, Ibbott G, Hobbs B, Yuan Y, Guerrero T. Assessment of a quantitative metric for 4D CT artifact evaluation by observer consensus. J Appl Clin Med Phys 15(3):4718, 2014. e-Pub 2014. PMID: 24892346.
248. Oki Y, Buglio D, Zhang J, Yuan Y, Zhou S, Sureda A, Ben-Yehuda D, Zinzani PL, Prince HM, Harrison SJ, Kirschbaum M, Johnston PB, Shen A, von Tresckow B, Younes A. Immune regulatory effects of panobinostat in patients with Hodgkin lymphoma through modulation of serum cytokine levels and T-cell PD1 expression. Blood Cancer J 4:e236, 2014. e-Pub 2014. PMID: 25105535.
249. Pan H, Zhu C, Zhang F, Yuan Y, Zhang S, Zhang W, Li C. The Continual Re- assessment Method for Multiple Toxicity Grades: A Bayesian Model Selection Approach. PLos ONE 9(e98147):1-8, 2014. PMID: None.
250. Ahn J, Liu S, Wang W, Yuan Y. Bayesian Latent-class Mixed-effect Hybrid Models for Dyadic Longitudinal Data with Non-ignorable Dropouts. Biometrics 69(4):914-24, 2013. e-Pub 2013. PMID: 24328715.
251. Shinn EH, Basen-Engquist K, Baum G, Steen S, Bauman RF, Morrison W, Garden AS, Sheil C, Kilgore K, Hutcheson KA, Barringer D, Yuan Y, Lewin JS. Adherence to preventive exercises and self-reported swallowing outcomes in post-radiation head and neck cancer patients. Head Neck 35(12):1707-12, 2013. e-Pub 2013. PMID: 24142523.
252. Liu S, Yin G, Yuan Y. Bayesian Data Augmentation Dose Finding with Continual Reassessment Method and Incomplete Observations. Ann Appl Stat 7(4):1837-2457, 2013. PMID: 24707327.
253. Schover LR, Yuan Y, Fellman BM, Odensky E, Lewis PE, Martinetti P. Efficacy trial of an internet-based intervention for cancer-related female sexual dysfunction. J Natl Compr Canc Netw 11:1389-97, 2013. PMID: 24225972.
254. Zang Y, Yuan Y. A shrinkage method for testing the hardy-weinberg equilibrium in case-control studies. Genet Epidemiol 37(7):743-50, 2013. e-Pub 2013. PMID: 23934751.
255. Yust-Katz S, Garciarena P, Liu D, Yuan Y, Ibrahim N, Yerushalmi R, Penas-Prado M, Groves MD. Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis. J Neurooncol 114(2):229-35, 2013. e-Pub 2013. PMID: 23756727.
256. Ahn J, Yuan Y, Parmigiani G, Suraokar MB, Diao L, Wistuba II, Wang W. DeMix: deconvolution for mixed cancer transcriptomes using raw measured data. Bioinformatics 29(15):1865-71, 2013. e-Pub 2013. PMID: 23712657.
257. Yust-Katz S, Liu D, Yuan Y, Liu V, Kang S, Groves M, Puduvalli V, Levin V, Conrad C, Colman H, Hsu S, Yung WK, Gilbert MR. Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma. Cancer 119(15):2747-53, 2013. e-Pub 2013. PMID: 23633392.
258. Fingeret MC, Hutcheson KA, Jensen K, Yuan Y, Urbauer D, Lewin JS. Associations Among Speech, Eating, and Body Image Concerns for Surgical Patients with Head and Neck Cancer. Head Neck 35(3):354-60, 2013. e-Pub 2012. PMID: 22431304.
259. Jin IH, Yuan Y Liang F. Bayesian analysis for exponential random graph models using the adaptive exchange sampler. Statistics and Is Interface 6:559-576, 2013. PMID: 3956133.
260. Cai C, Yuan Y, Johnson VE. Bayesian adaptive phase II screening design for combination trials. Clin Trials 10(3):353-62, 2013. e-Pub 2013. PMID: 23359875.
261. Zhang G, Yuan Y. Bayesian Modeling Longitudinal Dyadic Data with Nonignorable Dropout With Application to a Breast Cancer Study. Ann Appl Stat 6(2):753-771, 2012. PMID: 23814631.
262. Younes A, Oki Y, McLaughlin P, Copeland AR, Goy A, Pro B, Feng L, Yuan Y, Chuang HH, Macapinlac HA, Hagemeister F, Romaguera J, Samaniego F, Fanale MA, Dabaja BS, Rodriguez MA, Dang N, Kwak LW, Neelapu SS, Fayad LE. Phase II study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood 119(18):4123-8, 2012. e-Pub 2012. PMID: 22371887.
263. Yuan Y, Johnson VE. Goodness-of-Fit diagnostics for Bayesian Hierarchical Models. Biometrics 68(1):156-64, 2012. e-Pub 2011. PMID: 22050079.
264. Yuan Y, Thall PF, Wolff JE. Estimating progression-free survival in paediatric brain tumour patients when some progression statuses are unknown. J R Stat Soc Ser C Appl Stat 61(1):135-149, 2012. PMID: 22408277.
265. Schover LR, Canada AL, Yuan Y, Sui D, Neese L, Jenkins R, Rhodes MM. A randomized trial of internet-based versus traditional sexual counseling for couples after localized prostate cancer treatment. Cancer 118(2):500-509, 2012. e-Pub 2011. PMID: 21953578.
266. Koul D, Fu J, Shen R, LaFortune TA, Wang S, Tiao N, Kim YW, Liu JL, Ramnarian D, Yuan Y, Garcia-Echevrria C, Maira SM, Yung WK. Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. Clin Cancer Res 18(1):184-95, 2012. e-Pub 2011. PMID: 22065080.
267. Huo L, Yuan Y, Yin G. Bayesian Dose Finding for Combined Drugs with Discrete and Continuous Doses. Bayesian Anal 7(4):235-252, 2012. PMID: 23956811.
268. Karuturi M, Arai S, Chen R, Gopal A, Feng L, Yuan Y, Smith S, Ansell S, Rosenblatt J, Savage K, Ramchandren R, Bartel, N, Cheson B, Forero-Torres A, Moskowitz C, Connors J, Larsen E, Kennedy D, Sievers E, Fanale M, deVos S, Engert A, Illidge T, Borchmann P, Morschhauser F, Horning S, Younes A. Impact of Brentuximab Vedotin on Survival of Patients with classical Hodgkin Lymphoma treated with Prior Autologous Stem Cell Transplant. Journal of Clinical Oncology 120:3701, 2012. PMID: None.
269. Yao J, Zhao Q, Yuan Y, Zhang L, Liu X, Yung WK, Weinstein JN. Identification of common prognostic gene expression signatures with biological meanings from microarray gene expression datasets. PLoS One 7(9):e45894. 1-11, 2012. e-Pub 2012. PMID: 23029298.
270. Karuturi M, Arai S, Chen R, Gopal A, Feng L, Yuan, Y, Smith S, Ansell S, Rosenblatt J, Savage K, Ramchandren R, Bartlett N, Cheson B, Forero-Torres A, Moskowitz C, Connors J, Larsen E, Kennedy D, Sievers E, Fanale M, deVos S, Engert A, Illidge T, Borchmann P, Morschhauer F, Horning S, Younes A. Overall survival benefit for patients with relapsed Hodgkin lymphoma treated with Brentuximab Vedotin after autologous stem cell transplant. Blood 120:3701, 2012. PMID: None.
271. Yin G, Yuan Y. Bayesian model averaging continual reassessment method in phase I clinical trials. Journal of the American Statistical Association 104(487):954-968, 2012. PMID: None.
272. Yuan Y, Yin G. Dose-response curve estimation: A semiparametric mixture approach. Biometrics 67(4):1543-54, 2011. e-Pub 2011. PMID: 21627631.
273. Yin G, Ma Y, Liang F, Yuan Y. Stochastic generalized method of moments. J Comput Graph Stat 20(3):714-727, 2011. PMID: 22375093.
274. Yuan Y, Yin G. Robust EM continual reassessment method in oncology dose finding (featured article). J Am Stat Assoc 106(495):818-831, 2011. PMID: 22375092.
275. Yuan Y, Yin G. Bayesian hybrid design in phase I oncology clinical trials. Statistics in Medicine 30(17):2098-2108, 2011. e-Pub 2011. PMID: 21365672.
276. Fingeret MC, Yuan Y, Urbauer D, Weston J, Nipomnick S, Weber R. The nature and extent of body image concerns among surgically treated patients with head and neck cancer. Psychooncology 21:836-844. e-Pub 2011. PMID: 21706673.
277. Yuan Y, Huang X, Liu S. A Bayesian response-adaptive covariate-balanced randomization design with application to a leukemia clinical trial. Stat Med 30(11):1218-29, 2011. e-Pub 2011. PMID: 21432894.
278. Yuan Y, Yin G. Bayesian Phase I/II Adaptively Randomized Oncology Trials With Combinded Drugs. Ann Appl Stat 5(2A):924-942, 2011. PMID: 22375162.
279. Lei X, Yuan Y, Yin G. Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity. Lifetime Data Analysis 17(1):156-74, 2011. e-Pub 2010. PMID: 20364321.
280. Le-Petross HT, Whitman GJ, Atchely DP, Yuan Y, Gutierrez-Barrera A, Berry D, Hortobagyi GN, and Arun BK. Effectiveness of alternating mammography and magnetic resonance imaging for screening women at high risk of breast cancer. Cancer 117:3900-3907, 2011. PMID: None.
281. Song PX, Li M, Yuan Y. Rejoinder to "Joint regression analysis for discrete longitudinal data" by Madsen and Fang. Biometrics 67:1175-1176, 2011. PMID: None.
282. Yuan Y, Yin G. On adaptive randomization: is it useful?. Journal of Clinical Oncology 29:e390-e392, 2011. e-Pub 2011. PMID: None.
283. Carmack, CL, Basen-Engquist, K, Yuan, Y, Rodriguez-Bigas, M, Wolff, R, Barker T, Pennebaker J. Feasibility of an expressive-disclosure group intervention for post-treatment colorectal cancer patients: Results of the Healthy Expressions study. Cancer 117:4993-5002, 2011. PMID: None.
284. Yin G, Yuan, Y. Rejoinder to the correspondence of Gasparini, Bailey and Neuen- schwander on \Bayesian dose finnding in oncology for drug combinations by copula regression.". Journal of the Royal Statistical Society: Series C 59:544-546, 2010. PMID: None.
285. Yuan Y, Yin G. Quantile regression for longitudinal studies with nonignorable missing data. Biometrics 66:105-114, 2010. e-Pub 2009. PMID: 19459836.
286. Yuan Y, MacKinnon DP. Bayesian mediation analysis. Psychological Methods 14(4):301-22, 2009. PMID: 19968395.
287. Kiserud CE, Schover LR, Dahl AA, Fosså A, Bjøro T, Loge JH, Holte H, Yuan Y, Fosså SD. Do male lymphoma survivors have impaired sexual function?. J Clin Oncol 27(35):6019-26, 2009. e-Pub 2009. PMID: 19858388.
288. Yin G, Yuan Y. A latent contingency table approach to dose finding for combinations of two agents. Biometrics 65(3):866-75, 2009. e-Pub 2008. PMID: 18759848.
289. Yuan Y, Little RJ. Mixed-effect hybrid models for longitudinal data with nonignorable dropout. Biometrics 65(2):478-86, 2009. e-Pub 2008. PMID: 18759842.
290. Yuan Y, Little RJ. Meta-analysis of studies with missing data. Biometrics 65(2):487-96, 2009. e-Pub 2008. PMID: 18565168.
291. Song PX, Li M, Yuan Y. Joint regression analysis of correlated data using Gaussian copulas. Biometrics 65(1):60-68, 2009. e-Pub 2008. PMID: 18510653.
292. Yin G, Yuan Y. Bayesian dose-finding in oncology for drug combinations by copula regression. Journal of the Royal Statistical Society: Series C 58:211-224, 2009. PMID: None.
293. Yuan Y, Yin G. Bayesian dose-finding by jointly modeling toxicity and efficacy as time-to-event outcomes. Journal of the Royal Statistical Society: Series C 58:719-736, 2009. PMID: None.
294. Yin G, Yuan Y. Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials. Journal of the American Statistical Association 104:954-968, 2009. PMID: None.
295. Yuan Y, Yin G. Sequential continual reassessment method for two-dimensional dose finding. Statistics in Medicine 27(27):5664-78, 2008. PMID: 18618901.
296. Yuan Y, Johnson VE. Bayesian hypothesis tests using nonparametric statistics. Statistica Sinica 18:1185-1200, 2008. PMID: None.
297. Yuan Y, Little RJA. Model-based inference for two-stage cluster samples subject to nonignorable item nonresponse. Journal of Official Statistics 24(2):193-211, 2008. PMID: None.
298. Yuan Y, Little RJ. Parametric and semiparametric model-based estimates of the finite population mean for two-stage cluster samples with item nonresponse. Biometrics 63(4):1172-80, 2007. e-Pub 2007. PMID: 17489967.
299. Kolker JL, Yuan Y, Burt BA, Sandretto AM, Sohn W, Lang SW, Ismail AI. Dental caries and dietary patterns in low-income African American children. Pediatr Dent 29(6):457-64, 2007. PMID: 18254414.
300. Yuan Y, Little RJA. Model-based estimates of the finite population mean for two-stage cluster samples with unit non-response. Journal of the Royal Statistical Society:Series C 56(1):79-97, 2007. e-Pub 2007. PMID: None.
301. Zhou J, Yuan Y, Reynolds R, Raber S, Li Y. Cost-efficient higher-order crossover designs for two-treatment clinical trials. Clinical Pharmacokinetics 45:623-632, 2006. PMID: 16719543.
302. Burt BA, Kolker JL, Sandretto AM, Yuan Y, Sohn W, Ismail AI. Dietary patterns related to caries in a low-income adult population. Caries Res 40(6):473-80, 2006. PMID: 17063017.
303. Johnson VE, Yuan Y. Comments on 'An Exploratory Test for Excess of Signi. Clinical Trials 4(3):254-255; discussion 256-7, 2006. PMID: 17715250.
304. Yuan Y, Zhou J. Cost-Efficient Higher-Order Crossover Designs for Two-Treatment Clinical Trials. Pharmaceutical Statistics 4:245-252, 2005. e-Pub 2005. PMID: None.
305. Zhou J, He Y, Yuan Y. Comparison of Schuirmann's Two One-Sided Tests with Nonparametric Two One-Sided Tests for Non-normal Data in Clinical Drug-Drug Interaction Studies. Online Journal of Pharmacology and Pharmacokinetics 2:33-43, 2004. PMID: None.
306. Yuan Y, Wang ZH, Tang JG. Intra-A chain disulphide bond forms first during insulin precursor folding. Biochem J 343 Pt 1:139-44, 1999. PMID: 10493922.

Other Articles

1. Son J, Hsieh RC, Lin HY, Krause KJ, Yuan Y, Biter AB, Welsh J, Curran MA, Hong DS Inhibition of the CD47-SIRPα axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data. Front Immunol 13:1027235, 2022. PMID: 36439116.
2. Liu Y, Yuan Y, Day AJ, Zhang W, John P, Ng DJ, Banov D Safety and efficacy of compounded bioidentical hormone therapy (cBHT) in perimenopausal and postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. Menopause 29(4):465-482, 2022. PMID: 35357369.
3. Liu, S, Yuan, Y Erratum to. Journal of the Royal Statistical Society. Series C: Applied Statistics 71(2):491-492, 2022. PMID: None.
4. Yuan Y, Wu J, Gilbert MR BOIN: a novel Bayesian design platform to accelerate early phase brain tumor clinical trials. Neurooncol Pract 8(6):627-638, 2021. PMID: 34777832.

Abstracts

1. Zhou J, Yuan Y, Reynolds R, Raber S. Cost-efficient higher-order crossover designs in comparative bioavailability studies. Clinical Pharmacology and Therapeutics 77:90, 2005. PMID: None.

Book Chapters

1. Beibei G, Yuan Y. Precision Medicine Designs for Cancer Clinical Trials Statistics in Precision Health: Theory, Methods and Applications. In: None. None. New York: Springer, None, 2024.
2. Guo, B, Yuan, Y. Complex Innovative Design, 17-54, 2022.
3. Colbert, LE, Yuan, Y, Zindler, JD, Fuller, CD, Thomas CR. Radiotherapy Considerations and Strategic Approaches in Phase I Trials. In: Phase I Oncology Drug Development. None. None, 2020.
4. Yuan Y, Lin R. Novel Designs for Early Phase Drug Combination Trials. In: Bayesian Applications in Pharmaceutical Development. None. Taylor and Francis, 2019.
5. Yuan Y, Zhou Y, Lee JJ. Early Phase Clinical Trials. In: Principles of Clinical Cancer Research. None. Springer, 2019.
6. Yuan Y, Zhou H, Zhou Y. Phase I Cancer Clinical Trial Design: Single and Combination Agents. In: Biopharmaceutical Applied Statistics Symposium. None. Springer, 2018.
7. Yuan, Y, Zhang L. Designing Early-Phase Drug Combination Trials. In: Handbook of Methods for Designing and Monitoring and Analyzing Dose-Finding Trials. None. Chapman and Hall/CRC Press, 2017.
8. Zand Y, Yuan Y. Optimal Biomarker-guided Design for Targeted Therapy with Imperfectly Measured Biomarkers. In: Statistical Applications from Clinical Trials and Personalized Medicine to Finance and Business Analytics. None. Springer International Publishing, None, 2016.
9. Yuan Y, Ning J. Covariate-Balanced Bayesian Adaptive Randomization: Achieving Tradeoff Between Inferential and Ethical Goals in Small and Moderate Size Trials. In: Modern Adaptive Randomized Clinical Trials. None. CRC Press, 2015.
10. Yin G, Yuan Y. Bayesian approach for adaptive design. In: Handbook of Adaptive Designs in Pharmaceutical and Clinical Development. None. None, None, 2010.

Books (edited and written)

1. Pan H, Yuan Y. Bayesian Adaptive Design for Immunotherapy and Target Therapy. Ed(s) None. Springer, New York, 2023.
2. Yuan Y, Lin R, Lee JJ. Model-Assisted Bayesian Designs for Dose Finding and Optimization: Methods and Applications. Ed(s) None. Chapman and Hall/CRC, 2022.
3. Yuan Y, Nguyen H, Thall P. Bayesian Design for Phase I-II Clinical Trials,. Ed(s) None. Chapman and Hall/CRC Press, 2016.

Letters to the Editor

1. Zhou H, Yuan, Y, Nie L. Accuracy, Safety, and Reliability of Novel Phase I Designs--Response. Clinical Cancer Research 24: 4357-4364.